중화 항체 시장 예측 : 항체 유형, 유통 채널, 용도, 최종사용자 및 지역별 분석(-2034년)

According to Stratistics MRC, the Global Neutralizing Antibody Market is accounted for $257.5 billion in 2026 and is expected to reach $576.7 billion by 2034 growing at a CAGR of 10.6% during the forecast period. The immune system produces a kind of antibody known as neutralizing antibodies, which are designed to selectively target and inhibit the action of pathogens like bacteria or viruses. These antibodies stop pathogens from infecting or harming host cells by binding to particular areas, frequently on their surface. These antibodies aid the immune system in managing and curing the infection by blocking the pathogen's capacity to enter cells or multiply.

According to the report of GLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world, and increasing cancer cases are the major growth factor behind the market.

Market Dynamics:

Driver:

Rising numbers of infectious diseases

Infectious disorders including hepatitis, HIV/AIDS, and respiratory infections are still quite common around the world. A promising therapeutic strategy for the management of these illnesses is the use of neutralizing antibodies. Neutralizing antibodies should become more and more in demand as the incidence of these infectious illnesses rises. Furthermore, it is anticipated that the market would rise in response to the rising prevalence of autoimmune illnesses.

Restraint:

Regulatory challenges

Securing regulatory clearance for novel antibody treatments necessitates thorough assessments of their safety and effectiveness. Comprehensive clinical data is frequently required by regulatory bodies, which might result in lengthier development times and higher costs. Companies may find it difficult to navigate the regulatory environment, particularly when it comes to unique or complicated neutralizing antibodies. The market may be severely constrained by regulatory issues.

Opportunity:

Improvements in antibody engineering and design

Neutralizing antibodies that are optimized can be produced thanks to the ongoing advancements in antibody engineering and design approaches. Affinity maturation and antibody humanization are two techniques used to improve the safety, half-life, and effectiveness of antibodies. Adding new platforms to the mix, including antibody fragments and antibody-drug conjugates, increases the potential for developing therapeutics. This is the main factor driving the market's expansion.

Threat:

Expensive development and treatment costs

The process of creating and producing neutralizing antibodies is expensive and time-consuming. High development costs can be attributed to the considerable research and development activities, clinical trials, and manufacturing expenses. Furthermore, neutralizing antibody therapies might be prohibitively expensive, which may restrict accessibility, especially in healthcare systems with tight budgets and resources.

Covid-19 Impact:

The neutralizing antibody market has been significantly influenced by the COVID-19 pandemic. In order to treat and prevent COVID-19, neutralizing antibodies have been essential. Several monoclonal antibody treatments have been approved or authorized for usage in emergency situations. The market has grown significantly as a result of the spike in demand for neutralizing antibodies against SARS-CoV-2.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is expected to be the largest during the forecast period. The need for goods containing monoclonal antibodies, the expansion of the pharmaceutical and biotechnology sectors, and the availability of enhanced infrastructure for the healthcare industry are all anticipated to fuel the growth of the monoclonal antibody market. The healthcare industry is expanding quickly in emerging countries as a result of the rising need for more advanced sophisticated manufacturing systems and large government investments to modernize healthcare infrastructure.

The research institutes segment is expected to have the highest CAGR during the forecast period

The research institutes segment is expected to have the highest CAGR during the forecast period, owing to the increased incidence of cancer and other chronic illnesses within the anticipated time frame, several organizations have enhanced their research protocols and utilized the funds received to create novel technologies. Funded by public or commercial sources, research institutes conduct investigations on current or forthcoming products that have the potential to be utilized for the diagnosis, treatment, or surveillance of any human ailment.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the presence of a standard nationwide healthcare system and the existence of significant critical companies. The employment of cutting-edge genetic engineering technology in manufacturing, a sophisticated healthcare system, government support for infection control and management, and a rise in the prevalence of diseases associated with sedentary lifestyles are some of the factors driving the market's growth.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Factors driving the market expansion include the rise in technical demand for genetic platforms with improved capabilities, the expansion of research and development activities in the field of genomics, and the growing awareness among patients about the potential benefits of monoclonal antibodies (mAb) therapy. The market's growth is also fueled by the expansion of the R&D industry and technical advancements in the manufacturing of monoclonal antibodies.

Key players in the market

Some of the key players in Neutralizing Antibody market include GlaxoSmithKline plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Merck & Co.Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Moderna, Inc., Johnson & Johnson, BioNTech SE, CSL Limite, Sinovac Biotech Ltd and HaemaLogiX Ltd.

Key Developments:

In February 2022, Eli Lilly and Company announced that United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant.

In January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, a monoclonal antibody that binds to a cell surface target called kappa myeloma antigen (KMA) that is only found on myeloma cancer cells and not on normal plasma cells.

Antibody Types Covered:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Broadly Neutralizing Antibody
• Cross Neutralizing Antibody
• Other Antibody Types

Target Viruses Covered:

• SARS-CoV-2
• Influenza
• HIV
• Ebola
• Hepatitis C
• Zika
• Other Target Viruses

Distribution Channels Covered:

• Distributors
• Online Retail

Applications Covered:

• Diagnostics
• Therapeutics
• Research & Development
• Other Applications

End Users Covered:

• Hospitals
• Pharmaceutical Companies
• Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Neutralizing Antibody Market, By Antibody Type

• 5.1 Introduction
• 5.2 Monoclonal Antibodies
• 5.3 Polyclonal Antibodies
• 5.4 Broadly Neutralizing Antibody
• 5.5 Cross Neutralizing Antibody
• 5.6 Other Antibody Types

6 Global Neutralizing Antibody Market, By Target Virus

• 6.1 Introduction
• 6.2 SARS-CoV-2
• 6.3 Influenza
• 6.4 HIV
• 6.5 Ebola
• 6.6 Hepatitis C
• 6.7 Zika
• 6.8 Other Target Viruses

7 Global Neutralizing Antibody Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Distributors
• 7.3 Online Retail

8 Global Neutralizing Antibody Market, By Application

• 8.1 Introduction
• 8.2 Diagnostics
• 8.3 Therapeutics
• 8.4 Research & Development
• 8.5 Other Applications

9 Global Neutralizing Antibody Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Pharmaceutical Companies
• 9.4 Laboratories
• 9.5 Other End Users

10 Global Neutralizing Antibody Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 GlaxoSmithKline plc
• 12.2 Novartis AG
• 12.3 Regeneron Pharmaceuticals, Inc.
• 12.4 Roche Holding AG
• 12.5 Eli Lilly and Company
• 12.6 Sanofi SA
• 12.7 AstraZeneca PLC
• 12.8 Merck & Co.Inc.
• 12.9 Pfizer Inc.
• 12.10 Takeda Pharmaceutical Company Limited
• 12.11 Moderna, Inc.
• 12.12 Johnson & Johnson
• 12.13 BioNTech SE
• 12.14 CSL Limite
• 12.15 Sinovac Biotech Ltd
• 12.16 HaemaLogiX Ltd